Jacobs Levy Equity Management’s Aratana Therapeutics, Inc. PETX Stock Holding History

Jacobs Levy Equity Management’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-134,396	Closed	-$484K	–	1092
2019 Q1	$484K	Buy	134,396 +117,296	+686%	+$508K	0.01%	779
2018 Q4	$105K	Sell	17,100 -50,724	-75%	-$310K	﹤0.01%	940
2018 Q3	$396K	Sell	67,824 -78,367	-54%	-$392K	0.01%	823
2018 Q2	$621K	Buy	146,191 +61,791	+73%	+$312K	0.01%	757
2018 Q1	$372K	Buy	84,400 +16,600	+24%	+$74.1K	0.01%	825
2017 Q4	$357K	Buy	+67,800	New	+$415K	0.01%	817
2016 Q4	–	Sell	-113,300	Closed	-$1.06M	–	1112
2016 Q3	$1.06M	Buy	+113,300	New	+$941K	0.02%	569

Other funds holding PETX

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OAC

OMERS Administration Corp Toronto, Ontario, Canada $15.6B AUM 24.73% 1-Year Est. Return

Jacobs Levy Equity Management's PETX Position: Q2 2019 in Review

Jacobs Levy Equity Management sold out of Aratana Therapeutics, Inc. (PETX) in Q2 2019, closing a stake of 134,396 shares — an estimated $484K sold.

Jacobs Levy Equity Management first reported a position in PETX in Q3 2016 and held it in 7 quarters. The position peaked at $1.06M in Q3 2016. 103 funds tracked by Wall St. Rank hold PETX as of Q2 2019.

Jacobs Levy Equity Management reported no remaining Aratana Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
Jacobs Levy Equity Management sold 134,396 Aratana Therapeutics, Inc. shares in Q2 2019, an estimated $484K.
Jacobs Levy Equity Management first reported a position in Aratana Therapeutics, Inc. in Q3 2016 and held it in 7 quarters.
Jacobs Levy Equity Management's Aratana Therapeutics, Inc. position peaked at $1.06M in Q3 2016.
103 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q2 2019.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2019, filed 13 Aug 2019.